Local staging of de novo prostate cancer using mpMRI, PSMA-PET and PSMA-PET/mpMRI – a comparative study
Rattachement africain : se, dk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Accurate diagnosis and staging are essential for optimal treatment planning of prostate cancer. By combining functional and anatomical imaging, PSMA-PET/mpMRI offers a potential to improve lesion detection and enhance staging accuracy. This study aimed to evaluate the diagnostic performance of lesion detection and local staging of prostate cancer using combined PSMA-PET/mpMRI compared to standalone mpMRI or PSMA-PET. RESULTS: Ga]PSMA-PET/mpMRI prior to surgery. Whole-mount histopathology and surgical report served as reference standard. Two radiologists independently evaluated mpMRI, while two nuclear medicine physicians assessed PSMA-PET. For the PSMA-PET/mpMRI analysis, a consensus evaluation was performed by a new set of readers in two teams, each comprising one radiologist and one nuclear medicine physician. Lesion localization was reported based on the PI-RADS v2.1 sector map and compared to histopathology. Among 130 histopathologically confirmed lesions, mean detection rates were 38% (49.5/130) for PSMA-PET/mpMRI, 32% (41/130) for mpMRI and 32% (41/130) for PSMA-PET. For clinically significant prostate cancer (csPC) (≥0.5 ml, ≥ISUP 2; 42 lesions), mean detection rates were 85% (35.5/42) for PSMA-PET/mpMRI, 75% (31.5/42) for mpMRI and 70% (29.5/42) for PSMA-PET. The mean false discovery rates were 8% (PSMA-PET/mpMRI), 15% (mpMRI) and 12% (PSMA-PET). The likelihood of extraprostatic extension (EPE) and seminal vesicle invasion (SVI) were scored using a 5-point Likert scale, where scores of 1-3 were classified as negative and scores of 4-5 were considered positive. Sensitivity for EPE was 32% for PSMA-PET/mpMRI, 37% for mpMRI and 7% for PSMA-PET, with a specificity of 100%, 96% and 98%, respectively. For SVI, sensitivity was 50% for PSMA-PET/mpMRI and 38% for mpMRI and PSMA-PET, with a specificity of 100%, 95% and 97% respectively. CONCLUSIONS: PSMA-PET/mpMRI provided higher and a more consistent performance in localized prostate cancer detection and staging without increasing false-positive findings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Local staging of de novo prostate cancer using mpMRI, PSMA-PET and PSMA-PET/mpMRI – a comparative study
- Date Crossref
- 17/11/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Centre for Biomedical Engineering and Physics pays non établi dans la noticeOrganisation à but non lucratif
-
Umeå University Department of Diagnostics and Intervention pays non établi dans la noticeUniversité ou école supérieure
-
Karolinska University Hospital Department of Nuclear Medicine and Hospital Physics pays non établi dans la noticeÉtablissement de santé
-
Herlev Hospital pays non établi dans la noticeÉtablissement de santé
-
Copenhagen University Hospital Department of Radiology pays non établi dans la noticeÉtablissement de santé
-
Lund University Department of Translational Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Helsingborgs lasarett pays non établi dans la noticeÉtablissement de santé
-
Wallenberg Wood Science Center pays non établi dans la noticeStructure de recherche
-
Skåne University Hospital Department of Medical Imaging and Physiology pays non établi dans la noticeÉtablissement de santé
-
Helsingborg Hospital Department of Radiology pays non établi dans la noticeÉtablissement de santé
Centre for Biomedical Engineering and Physics, Department of Diagnostics and Intervention — Umeå University et Department of Nuclear Medicine and Hospital Physics — Karolinska University Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.